HFE is the protein product of the gene mutated in the autosomal recessive disease hereditary hemochromatosis (1) , which was first cloned in 1996 (1) . It is therefore a relatively new member of the growing group of proteins involved in iron metabolism. HFE is remarkable in that it is a nonclassical major histocompatibility complex class I type molecule, a characteristic that prevented its role in iron homeostasis from being recognized immediately. Over 80% of hereditary hemochromatosis patients have the same mutation in the ␣ 3 domain of HFE that prevents its heterodimerization with ␤ 2 microglobulin (2). Consistent with the classification of HFE as an major histocompatibility complex class I type molecule, this C282Y mutation has been shown to prevent cell surface expression and, presumably, function of the protein (2, 3) . The generation of the HFE knockout mouse supports the finding that the C282Y mutation is, indeed, a loss of function mutation because the phenotype of the knockout mouse parallels the manifestation of hereditary hemochromatosis in humans (4) .
Although the gene encoding HFE was discovered by genetic mapping of individuals with a disease of iron overload, the function of the protein in iron metabolism has not been immediately appreciated. The region of the HFE molecule normally associated with peptide binding and cell surface presentation in major histocompatibility complex class I molecules is too narrow to bind peptides. HFE does not appear to bind iron either (5) . HFE does, however, associate with the transferrin receptor (TfR), 1 a well characterized member of the iron metabolic pathway. The TfR is a type II transmembrane protein that binds the serum protein, diferric transferrin (Tf), at the cell surface. The Tf-TfR complex is constitutively taken into the cell through clathrin-mediated endocytosis. At the low pH of the endosome, a conformational change in the TfR facilitates iron release from Tf (6 -9) . Apotransferrin (apo-Tf) remains bound to TfR until the complex cycles back to the cell surface. At the neutral pH of the extracellular environment, apo-Tf is quickly replaced by diferric Tf and is free to bind more iron (for further discussion, see reviews in Refs. 10 and 11) .
The association of HFE with the TfR has been demonstrated in tissues and in cell culture (12, 13) . Wild type HFE has been shown to associate with TfR in the placenta (13) and to have the same immunohistochemical staining pattern as TfR in the crypt cells of the intestine (14) . In cultured cells, HFE traffics with TfR between the cell surface and Tf-positive perinuclear compartments (15) . The association between HFE and TfR has been shown to lower the affinity of TfR for its ligand 10-fold (5, 12, 15) . Other nonclassical major histocompatibility complex class I molecules have been shown to affect ligand affinity for other receptors, such as the ability of the HLA H-2 protein to associate with the insulin receptor and reduce all insulin binding sites to low affinity sites (16 -20) and the ability of anti-HLA antibodies to reduce epidermal growth factor binding to its receptor (21, 22) .
The physiological importance of the interaction between HFE and TfR is not immediately clear. Diferric Tf is present at concentrations of approximately 5 M in the blood (23) . The dissociation constant of Tf for the TfR-HFE complex is approximately 11 nM. Thus, the binding of diferric Tf to its receptor is saturated in the presence of HFE. These results emphasize the putative role of HFE as a regulator of iron homeostasis that acts through the TfR cycle rather than having a role as a transporter or iron-binding protein.
To investigate its influence on cellular iron metabolism, the ability of HFE to specifically regulate the Tf-mediated pathway of iron uptake was tested. We found that HFE does not alter the cycling kinetics of the TfR. Rather, HFE reduces the amount of iron assimilated from Tf by ϳ33% without affecting non-Tf-mediated uptake of Fe-NTA. This finding gives more insight into the role of HFE as an iron regulator through the Tf-mediated pathway. Additionally, this focuses attention on the role of Tf-iron stores as a critical part of the "sensing machinery" that regulates dietary iron uptake and the kinetics of metabolic iron recycling.
EXPERIMENTAL PROCEDURES

Cell Lines
The fWTHFE/tTA HeLa cell line expressing FLAG epitope-tagged HFE (fHFE) under the tetracycline-responsive promoter has been previously described (15) . Cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 400 g/ml G418 (Geneticin, Calbiochem), 200 ng/ml puromycin, and with (HFEϪ) or without (HFEϩ) 2 g/ml tetracycline.
Iodination
Human holotransferrin (Intergen, Co.) was labeled with Na[
125 I] (NEN Life Science Products) using lactoperoxidase as described previously (24) .
I-Tf Uptake Protocol
The rate of 125 I-Tf uptake was determined as described previously (24) with the following modifications. Uptakes were performed on subconfluent HFEϪ and HFEϩ fWTHFE/tTA HeLa cultures (ϳ1 ϫ 10 6 cells) washed two times with 2 ml of DMEM-20 mM HEPES, pH 7.4, and preincubated in the same medium for 15 min at 37°C with 5% CO 2 . At the 0 min mark, 1 ml of specific (DMEM-20 mM HEPES, 2 mg/ml ovalbumin, 50 nM 125 I-Tf) or nonspecific (specific medium with 1 mg/ml cold Tf) medium was added to the appropriate cells. Cells were incubated at 37°C with 5% CO 2 for 2, 4, 6, or 8 min. Externally bound Tf was stripped with an acidic buffer (0.5 N acetic acid, 0.5 M NaCl) for 3 min at 4°C. Then, the cells were washed four times with 2 ml of 4°C final wash buffer (150 mM NaCl, 20 mM HEPES, 1 mM CaCl 2 , 5 mM KCl, 1 mM MgCl 2 , pH 7.4) before addition of solubilization detergent (0.1% Triton X-100, 0.1% NaOH) and counting in a gamma counter (Packard, CobraII Auto-Gamma). Surface TfR numbers were determined by counting the amount of 125 I-Tf bound after incubation with 50 nM 125 I-Tf for 90 min on ice at 4°C. Following the 90-min incubation, the medium was removed, and cells were washed four times with 2 ml of 4°C final wash buffer before solubilization and counting.
I-Tf Efflux Protocol
The rate of Tf efflux was determined as described previously by McGraw and Maxfield (25) with the following modifications. Monolayers of subconfluent HFEϪ and HFEϩ fWTHFE/tTA HeLa cells grown in 35-mm plates were washed three times with 2 ml of DMEM-20 mM HEPES and then preincubated in the same medium for 15 min at 37°C and 5% CO 2 . The medium was removed, and cells were incubated for 2 h with specific (50 nM 125 I-Tf in DMEM-20 mM HEPES and 2 mg/ml ovalbumin) or nonspecific (specific medium with 1 mg/ml unlabeled Tf) medium at 37°C and 5% CO 2 . Cells were washed with 2 ml of 37°C mild acid buffer (500 mM NaCl, 50 mM MES, pH 5.0) for 2 min and then washed two times with 2 ml of 37°C final wash buffer with 100 M desferoxamine (desferal; Ciba-Geigy Ltd.; Basel, Switzerland) and 3 g/ml Tf to prevent loading and rebinding of apo-125 I-Tf. 1 ml of 37°C medium (DMEM-20 mM HEPES, 2 mg/ml ovalbumin) with 3 g/ml Tf and 100 M desferoxamine was added at the 0 min mark, and then at each of the appropriate time points, plates were placed on ice and the appropriate efflux, surface and internal samples were collected as follows.
Efflux-Medium was removed by pipetting, and cells were washed one time with 1 ml of final wash, which was pooled and counted in gamma counter (Packard, CobraII Auto-Gamma).
Surface-Cells were incubated in 1 ml of acid wash (0.2 N acetic acid, 0.5 M NaCl) for 3 min at 4°C and then washed 1 time with 1 ml of final wash, which was pooled and counted.
Internal-Cells were stripped and washed as per surface samples and then solubilized in 2 ml of solubilization detergent and counted.
TfR Distribution
The relative TfR distribution between cell surface (external) and internal compartments was determined as described previously (25, 26) with the following modifications. Subconfluent HFEϪ and HFEϩ fWTHFE/tTA HeLa cells grown in 35-mm plates were either incubated for 90 min with 100 nM 125 I-Tf at 37°C with 5% CO 2 for total and internal measurements or with 100 nM 125 I-Tf at 4°C for external measurements in 1 ml of specific (100 nM 125 I-Tf in DMEM-20 mM HEPES) or nonspecific (specific medium with 1 mg/ml unlabeled Tf) medium at 4°C. At the end of the incubation time, cells were placed on ice. Total and external measurements were determined by washing four times with 2 ml of final wash at 4°C and then solubilizing and counting. The amount of internalized 125 I-Tf was determined by stripping the surface for 3 min with acid wash, washing four times with 2 ml of final wash, and then solubilizing and counting in gamma counter (Packard, CobraII Auto-Gamma). Fe-Tf and 2 mg/ml ovalbumin in wash medium (McCoy's 5A with 20 mM HEPES). Nonspecific medium was the same as specific with the addition of 1 mg/ml unlabeled Tf. After 45, 90, 135, or 225 min of uptake, cells were placed on ice, and externally bound Tf was stripped with an acidic buffer (0.2 N acetic acid, 500 mM NaCl, 1 mM FeCl 3 ) for 3 min at 4°C. Cells were solubilized in 1 ml of the same solubilization detergent described above. Lysates were mixed with 6 ml UniverSol (ICN) and counted for 10 min in a scintillation counter (Beckman LS 6000SC) with a window of 0 -350 nm. TfR numbers were determined as described for the 125 I-Tf uptake protocol above. 55 Fe-NTA in wash medium) or nonspecific (specific medium with 1 mM Fe-NTA) medium. After 2, 5, 10, 15, or 30 min of uptake, cells were placed on ice, and 3 ml of 4°C quench buffer (1 mM Fe-NTA, 25 mM HEPES, 150 mM NaCl) was added for 20 min. Finally, the cells were washed three times with 2 ml of 150 mM NaCl at 4°C, solubilized, and counted as for 55 Fe-Tf uptake protocol described above.
Iron Treatments
HFEϪ and HFEϩ fWTHFE/tTA HeLa cells were seeded at ϳ1.5 ϫ 10 5 cells per 35-mm dish. After 2 days, cells were treated with either 50 M desferoxamine, 100 nM human holotransferrin (Intergen Co.), or 100 M Fe-NTA overnight. Cells were lysed in NET-Triton (150 mM NaCl, 5 mM EDTA, and 10 mM Tris (pH 7.4) with 1% Triton X-100) after at least 12 h of treatment.
Western Immunodetection
Cell extracts from 2 ϫ 10 5 cells were diluted with 4ϫ Laemmli buffer (28) to 62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 5% 2-mercaptoethanol and subjected to electrophoresis on 12% SDS-polyacrylamide gels under reducing conditions. The proteins were transferred to nitrocellulose. Immunoblot analysis was performed using sheep anti-human transferrin receptor serum (described previously (24); 1:10,000 dilution), and sheep anti-human ferritin antibody (The Binding Site, Ltd., 1:100 dilution) followed by swine anti-goat secondary antibody conjugated to horseradish peroxidase (Boehringer Mannheim). Chemiluminescence (SuperSignal, Pierce) was performed per the manufacturer's directions.
RESULTS
fHFE Does Not Alter Tf Endocytosis-The influence of HFE on TfR cycling kinetics was measured to determine how HFE regulates iron levels in the cell. In previous studies, a cell line expressing fHFE under the control of the tetracycline repressible system was established (15) . Induction of HFE expression by the withdrawal of tetracycline from the medium results in decreased ferritin (Ft) levels. One mechanism by which HFE could lower the amount of iron taken up into cells would be by decreasing the rate of endocytosis of the TfR. HFE co-traffics with TfR between the cell surface and Tf positive perinuclear compartments (15) and therefore might have some influence on TfR endocytic kinetics.
The rate of 125 I-Tf uptake was measured to test whether or not HFE alters the endocytosis of TfR and therefore the amount of Tf-mediated iron uptake in fWTHFE/tTA HeLa cells expressing fHFE (fWTHFE/tTA HeLa cells). Uptake experiments were performed in the presence of 50 nM 125 I-Tf. The association of HFE with the TfR decreases the affinity of the TfR for Tf, resulting in an increase in the K d from 1.2 to 11 nM (15) . At 50 nM Tf, essentially all the TfRs are occupied with Tf, even in the presence of HFE. Cells were incubated with 125 I-Tf for 2, 4, 6, or 8 min at 37°C with 5% CO 2 . The surface was stripped of bound Tf, and the amount of 125 I-Tf inside the cell was counted. Both HFEϪ and HFEϩ cells took up approximately 0.20 Tf/surface TfR/min (Fig. 1) . The same rates of internalization were measured in cells treated with 100 nM 125 I-Tf, confirming that the binding of Tf to its receptor was rapid and saturating (data not shown). fHFE did not significantly alter the amount of 125 I-Tf uptake per TfR in fWTHFE/ tTA cells and therefore did not affect the kinetics of TfR endocytosis.
fHFE Does Not Alter TfR Exocytosis-The amount of iron taken up into cells is a function of the kinetics of TfR cycling that depends on both the endocytic and exocytic rates. Because fHFE had no effect on TfR endocytosis, the rate of 125 I-Tf release was measured to test whether fHFE alters the exocytic rate of TfR in HFEϪ and HFEϩ fWTHFE/tTA HeLa cells. Cells were loaded with 125 I-Tf for 2 h at 37°C with 5% CO 2 to saturate internal and external TfR with Tf. Then, the cell surface was stripped of Tf, and fresh medium was added to the cells. The Tf released from internal cellular compartments was collected and counted at 2, 4, 6, and 8 min time points. HFEϪ and HFEϩ fWTHFE/tTA HeLa cells did not differ significantly in their rate of TfR exocytosis (Fig. 2) .
TfR Distribution Is Not Changed in fHFE-expressing CellsBecause the uptake and efflux kinetics of Tf did not change with the expression of fHFE, the steady state distribution of external and internal TfRs should also remain the same between cells expressing and not expressing fHFE. To test this prediction, steady state external and internal pools of 125 I-Tf were measured in control cells (HFEϪ) and in cells expressing fHFE (HFEϩ). fHFE expression did not significantly alter the relative surface and internal distributions of TfR (Fig. 3) . Approximately 20% of cellular TfR was found at the cell surface, whereas 80% was found in internal vesicles. The distribution of TfR between the cell surface and internal compartments was similar to that reported previously in other cell lines expressing similar amounts of TfR (29 -31) . Combined with the uptake and efflux data reported above, these findings support the conclusion that HFE has no effect on TfR cycling kinetics even though HFE associates and co-traffics with the TfR (15) .
fHFE Reduces Iron Uptake from Tf But Does Not Alter NonTf-mediated Iron Uptake-We wanted to determine whether HFE affected the amount of Tf-mediated or non-Tf-mediated iron uptake because no effect on the cycling kinetics of the TfR was detected. HFEϪ (Fig. 4) . These data show that HFE-expressing cells take up approximately 33% less iron from Tf than control cells that do not express fHFE.
To determine whether the influences of HFE are restricted to the Tf-mediated pathway of iron uptake or if HFE additionally affects the non Tf-mediated iron uptake pathway, HFEϪ and HFEϩ fWTHFE/tTA HeLa cells were incubated in the presence of 200 nM 55 Fe-NTA for up to 30 min. No significant difference was seen in iron uptake between HFEϪ and HFEϩ cells (Fig.  5) . Combined, these results support the conclusion that the regulation of iron uptake by HFE is specific to the Tf-mediated iron uptake pathway. The effect of HFE on Tf-mediated iron uptake is therefore a direct effect on the Tf-derived iron pathway rather than an alteration of all cellular iron metabolism.
Ft Levels Are Responsive to Iron Treatment in fWTHFE/tTA HeLa Cells-The response of HFEϪ and HFEϩ fWTHFE/tTA HeLa cells to iron loading or iron chelation was observed by detection of TfR and Ft levels on Western blots. These experiments were performed to test whether HFE affects the ability of the cells to compensate for changing iron levels in the medium as predicted by the known influences of iron regulatory proteins (IRPs) on Ft and TfR expression. IRPs are the most extensively characterized mode of regulating intracellular iron concentrations. In the presence of low intracellular iron, IRPs bind to iron responsive elements in the mRNA of iron-regulated proteins. This interaction either stabilizes the mRNA by binding to the 3Ј-end of the transcript (as is the case for TfR mRNA), or blocks translation by binding to the 5Ј-end of the transcript, close to the site of translation initiation (as is the case for Ft mRNA). Thus, at low intracellular iron levels, the cell increases iron uptake by increasing TfR levels. It decreases iron storage by lowering Ft levels. When intracellular iron concentrations are high enough, the IRP no longer binds the iron responsive element. This acts to reduce iron uptake from Tf by reducing TfR levels and increasing Ft levels.
The response of cells to iron depletion and iron loading was measured in HFEϪ and HFEϩ fWTHFE/tTA HeLa cells grown for 2 days in untreated growth medium and treated for at least 12 h with growth medium supplemented with 50 M desferoxamine to chelate iron, human Tf, or Fe-NTA. Under control conditions, cells expressing fHFE had no detectable Ft over background, whereas those that do not express HFE showed significant amounts of Ft (Fig. 6) in HFEϩ cells without Tf treatment. In the same way, both HFEϪ and HFEϩ cells showed increased Ft expression following treatment with 100 M Fe-NTA.
TfR levels also changed, as shown in Fig. 6 , as predicted by the known influence of IRPs. TfR levels were slightly elevated in fHFE-expressing cells versus HFEϪ cells in keeping with their iron-depleted status. Both HFEϪ and HFEϩ cells treated with desferoxamine showed increased TfR levels above that in untreated cells. For both HFEϪ and HFEϩ cells, TfR levels slightly decreased upon treatment with human Tf or Fe-NTA as compared with untreated cells. These results demonstrate that the outcome of the iron-responsive mechanisms used by the cell are not perturbed by HFE expression. Rather, HFE imposes an additional but separate homeostatic mechanism.
The sensitivity of the cellular IRP response to iron was also tested in the presence and absence of HFE. Even at Tf concentrations below saturation of the TfR and HFE/TfR complex, such as 5 nM, Ft levels were greater for both HFEϪ and HFEϩ cells than without Tf treatment (Fig. 7) . However, due to the difference in the Tf binding affinity and the reduced iron uptake from Tf, HFEϩ cells expressed consistently smaller amounts of Ft than HFEϪ cells under the same Tf concentrations below 50 nM. Ft levels were also increased in HFEϪ and HFEϩ cells when treated with Fe-NTA at concentrations as low as 50 nM. Ft levels for HFEϩ cells remained lower than HFEϪ cells due to their initially depressed intracellular iron levels. The observation that the cells responded to Tf-derived iron at much lower concentrations than NTA-derived iron is consistent with the association constants and the kinetics of the protein components of those systems. Detection limits of the enhanced chemiluminescence and x-ray film prevent quantitative conclusions from these data; however, the qualitative results provide strong evidence that HFE does not prevent the IRP-dependent regulation of Ft and TfR expression. Rather, HFE alters the "set point" of intracellular iron levels in a Tf-mediated manner.
DISCUSSION
The mechanism by which HFE controls iron homeostasis is not yet known. We have previously reported that HFE specifically reduces Ft levels in HeLa cells expressing fHFE, showing a direct relationship between HFE expression and cellular iron homeostasis (15) . HFE traffics with TfR to Tf-positive perinuclear vesicles, which are one site of cellular iron absorption (15) . Regulated Tf and non-Tf-mediated iron uptake pathways have both been described for the HeLa tissue culture system (32-34) (for further discussion, see review in Ref. 35 ). This study shows that HFE specifically decreases the Tf-mediated pathway of iron uptake. fHFE has no effect on the kinetics of TfR cycling in cells. If HFE were to slightly decrease the endocytic rate or increase the exocytic rate of TfR, less Tf and therefore less iron would be taken up per unit of time. At concentrations of Tf that saturate Tf binding to the HFE/TfR complex (50 -100 nM), no difference in the uptake or release of 125 I-Tf from HFEϪ and HFEϩ fWTHFE/tTA HeLa cells was detected. These results were confirmed by measuring the steady state distribution of TfRs. No redistribution of TfRs was detected between the cell surface and internal compartments when fHFE is expressed at steady state.
Although HFE does not affect TfR cycling kinetics, it does regulate cellular iron homeostasis through the Tf-mediated iron uptake pathway. At saturating concentrations of 55 Feloaded Tf (100 nM), 33% less iron was taken up by fWTHFE/tTA HeLa cells expressing fHFE. Because saturating amounts of Tf were used in these experiments, the ability of HFE to lower the TfR affinity for Tf is not the mechanism responsible for the observed decrease in cellular iron. This experiment does not differentiate between release of iron from transferrin and transport across the endosomal membrane to the cytoplasm. HFE might effect either of these steps in Tf-mediated iron transport. Because Ft levels are also reduced for HFEϩ fWTHFE/tTA HeLa cells in culture, these results suggest that acquisition of iron from fetal bovine Tf in tissue culture medium takes place through the TfR. Despite the larger dissociation constant of fetal bovine Tf for the human TfR, iron is still removed from the bovine Tf but the uptake is reduced in HFEϩ cells.
fWTHFE/tTA HeLa cells were incubated in the presence of 200 nM 55 Fe-NTA to confirm that HFE specifically regulates Tf-mediated iron uptake. Iron presented in this form bypasses the Tf-TfR pathway and enters the cell directly through a transporter (27, 36) . Candidate transporters are SFT and DCT1/Nramp2 although other, currently unidentified, cell surface iron transporters may exist as well (34, 37) . No significant difference was seen in the amount of non-Tf bound iron taken up by HFEϩ cells as compared with HFEϪ cells, suggesting that HFE acts specifically through the Tf/TfR-mediated pathway of iron uptake.
Western blots were used to determine whether cells expressing HFE can respond to bioavailable iron by increasing their Ft levels. Under control tissue culture conditions, HFEϪ cells have more Ft than HFEϩ cells. Cells that do not express fHFE are capable of depleting Ft levels under low iron conditions, such as in the presence of the iron chelator desferoxamine. Both HFEϪ and HFEϩ fWTHFE/tTA HeLa cells responded to iron loading via the Tf-mediated and non-Tf-mediated pathways by increasing intracellular Ft levels and decreasing TfR levels. These results emphasize that cells expressing HFE still regulate Ft levels under high and low iron conditions, presumably through the translational regulation of Ft by the IRPs. HFE has simply changed the total amount of iron that is stored within the cell.
These studies demonstrate that in a nonpolarized cell line, fHFE reduces the amount of iron taken up from the Tf-mediated iron uptake pathway. Several factors are involved in iron uptake from the endosome, any one of which could be affected by HFE. One characteristic of the endosome is its relatively low pH (between 5.5 and 6.5, depending on the cell type (9)). This low pH is responsible for a conformational change in both Tf and the TfR that facilitates the release of iron (6 -9) . HFE might regulate the lumenal pH of the endosome, preventing efficient removal of iron from Tf. In conflict with this hypothesis is evidence that suggests increases in endosomal pH slows recycling of TfR (38) . We do not see any perturbations of TfR recycling, suggesting that the endosomal pH is close to normal.
We favor the hypothesis that HFE prevents the pH-induced conformation of the TfR that potentiates the release of iron from Tf. Aisen and co-workers (6 -8) and Sipe and Murphy (9) showed the importance of the TfR-induced conformational change in Tf for the release of iron in the endosome. At pH 6.0, the association of Tf with the TfR approximately doubles the rate of loss of iron from Tf (39) . If this change was prevented, then less iron would be taken up into cells. One caveat of this hypothesis is the observation that soluble TfR does not detectably bind to soluble HFE at pH 6.0 (5). For this mechanism to be responsible for the lower uptake of iron into cells, either HFE does interact with the TfR at the slightly higher pH of many endosomes or the membrane bound forms of the TfR and HFE interact with each other at endosomal pHs.
Alternatively, HFE might regulate the function of one of the known endosomal iron transporters, such as Nramp2/DCT1 or SFT (40, 41) , thereby reducing iron transport across the endosomal membrane. HFE might simply use its association with TfR for endocytosis. Once in the endosome, HFE might complex with transmembrane proteins responsible for transporting, iron into the cytoplasm. HFE could modulate the transporters affinity for iron or its kinetics of iron transport across the endosomal membrane. Thus, HFE may be involved in maintaining homeostatic equilibrium of iron through its regulation of such a transporter. By modulating transporter activity in Tf-positive endosomes, HFE could facilitate appropriate flux of Tf-derived iron across the intestinal enterocyte. These three hypothesis need to be tested.
With the addition of the present findings from the fWTHFE/ tTA HeLa system, we propose a new model for the role of HFE in iron regulation (Fig. 8) . HFE imposes an additional regulatory step for iron uptake in cells expressing HFE. Iron responsive element-mediated iron regulation does not appear to be sufficient to regulate iron homeostasis because organisms lacking HFE or Tf but having functional IRPs eventually succumb to iron overload. We propose that HFE limits iron uptake from Tf by reducing the amount of iron released from Tf. Without HFE (as is the case in hereditary hemochromatosis patients), organs normally expressing HFE, such as the lives, clear more iron from circulating Tf, contributing to hepatic iron overload.
We have shown previously that HFE co-traffics with TfR from the time of its initial synthesis to its cycling through Tf-positive endosomes (15) . HFE may traffic with TfR from the basolateral plasma membrane to endocytic vesicles of the enterocytes. This would be consistent with the perinuclear immunohistochemical staining of HFE (14) and TfR localization (42) in the cells of the intestinal crypts. HFE in the enterocyte endosome, where iron derived from apical dietary uptake and iron derived from bodily Tf stores meet, may play a key role in the regulation of iron transport out of the enterocyte into the blood. The mechanisms for such events remain unresolved. (43) and is therefore capable of saturating all TfRs, even in the presence of HFE (arrow 1A). HFE traffics with Tf and TfR to the endosome (arrow 2A). Once the endosome has acidified, iron is released from transferrin and transported through an endosomal iron transporter, such as Nramp2/DCT1 or SFT (arrow 3A). In the presence of HFE, TfR does not potentiate the full release of iron from Tf, leaving some iron bound to Tf. Tf then cycles out of the endosome and back to the cell surface, resulting in release of ferric rather than apo-Tf (arrow 4A). TfR that is not associated with HFE (as is the case in HH patients) also binds diferric Tf preferentially at the cell surface (arrow 1B). TfR internalization is identical to that of the TfR/HFE complex (arrow 2B). Once the endosome has acidified, TfR potentiates the release of iron from Tf, which is transported across the endosomal membrane (arrow 3B). More iron is released from Tf that is bound to TfR alone than is released from Tf bound to the HFEϪTfR complex. Tf then cycles out of the endosome and back to the cell surface, where apo-Tf is released (arrow 4B).
